Seattle Genetics Inc. (SGEN)
Symbol Info
Listed Symbol SGEN
Name Seattle Genetics Inc.
Share Info
Annual Info
Latest Fiscal Dividend Per Share $-
Latest Fiscal Date 2018-12-31
Latest Fiscal Revenue $654,700,000
Latest Fiscal EPS $-1.43
Price Info
21 Day Moving Average $81.0657
21 Day EMA $81.358530
50 Day Moving Average $77.0066
50 Day EMA $77.913170
200 Day EMA $72.475010
200 Day Moving Average 72.443750
52 Week High $88.68
52 Week Low $50.71
52 Week Change $18.556700
Alpha 0.007974
Beta 1.9526
Standard Deviation 0.122428
R2 0.299983
Periods 60
Share Information
10 Day Average Volume 906,838
20 Day Average Volume 1,111,831
30 Day Average Volume 972,966
50 Day Average Volume 833,240
Outstanding Shares 161,720,181
Float Shares 159,131,507
Percent Float 98.40%
Short Interest -
Short Percent Float -
Short Interest Ratio -
Short Date
Holders
Institutions 709
Institute Holdings Date 2019-09-30
Institute Bought Previous 3 Months 6,680,652
Institute Holdings Percent -
Institute Sold Previous 3 Months 7,980,238
Insider Holdings Date 2019-08-31
Insider Bought Previous 3 Months 14
Insider Holdings Percent 1.60%
Insider Sold Previous 3 Months -
Insiders Shares Owned 2,588,674
Price Change
7 Day Price Change $4.8000030
7 Day Percent Change 5.81%
21 Day Price Change $11.4000020
21 Day Percent Change 15.00%
30 Day Price Change $14.5700000
30 Day Percent Change 20.01%
Month To Date Price Change $2.0000
Month To Date Percent 2.34%
90 Day Price Change $10.760002
90 Day Percent Change 14.04%
Quarter To Date $2.000000
Quarter To Date Percent 2.34%
180 Day Price Change $18.220001
180 Day Percent Change 26.34%
200 Day Price Change $13.790001
200 Day Percent Change 18.73%
Year To Date $30.740002
Year To Date Percent 54.25%
Profile
Description Seattle Genetics is a biotech firm focused on the development of monoclonal antibody-based therapies. The company's lead product, Adcetris, has received approval for advanced frontline, relapsed/refractory and post-consolidation Hodgkin lymphoma, anaplastic large-cell lymphoma, and two other subtypes of cutaneous T-cell lymphoma. The company has several other early-stage programs in trials. Seattle Genetics also licenses its antibody-drug conjugate technology to a number of leading biotechnology and pharmaceutical companies.
Details
Issue Type CS
Market Cap $14,134,343,819
Sec Type EQS
Auditor PricewaterhouseCoopers LLP
Total Shares Outstanding 161,720,181
CEO Clay B. Siegall
Employees 1,302
Last Audit UE
Classification
CIK 0001060736
Industry Biotechnology
Sector Healthcare
NAICS Biological Product (except Diagnostic) Manufacturing(325414)
Info
Address 21823 - 30th Drive South East
Building 3
Bothell, WA 98021
Website http://www.seattlegenetics.com
Facisimile +1 425 527-4001
Telephone +1 425 527-4000
Email investors@seagen.com
Key Ratios
Profitability
EBIT Margin -30.1
EBITDA Margin -26.5
Pre-Tax Profit Margin -33.3
Profit Margin Cont -36.11
Gross Margin 90.20
Profit Margin TOT -36.11
Income Statements
Revenue $588,159,000
Revenue Per Share $3.6369
Revenue 3 Years $14.61
Revenue 5 Years $17.87
Valuation Measures
PE Ratio -
Enterprise Value $13,514,153,457
Price To Sales 24.031502
Price To Free Cash -88.1
PE High Last 5 Years -
Price To Book 10.8
Price To Cash Flow 515.4
PE Low Last 5 Years -
Price To Tangible Book 19.6
Financial Strength
Total Debt To Equity 0.1
Int Coverage -
Current Ratio 3.0
Leverage Ratio 1.2
Quick Ratio 2.5
Long Term Debt To Capital 0.05
Assets
Receivables Turnover 1.7
Invoice Turnover 1.00
Assets Turnover 0.20
Management Effectiveness
Return Assets -17.77
Return On Equity -21.08
Return On Capital -19.89
Dividends
Dividend 3 Years $-
Dividend 5 Years $-
Ex Dividend Date
Dividend Rate $-
Dividend Yield -
Payment Type


Your Recent History
NASDAQ
SGEN
Seattle Ge..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.


NYSE, AMEX, and ASX quotes are delayed by at least 20 minutes.
All other quotes are delayed by at least 15 minutes unless otherwise stated.